Goodwin Biotechnology Inc, a full service Contract Biomanufacturing Company and Macrocyclics, Inc, a manufacturer of customized chelating agents, jointly announced their collaborative agreement on Chelation and Bioconjugation. The collaboration will strengthen joint customer projects in Nuclear Medicine involving Chelation, Bioconjugation and GMP manufacturing.

"Clinical development programs in nuclear medicine with biotargeted agents require combining chelation chemistry and bioconjugation chemistry to create a product," said Garry E Kiefer, chief executive officer at Macrocyclics. "In Goodwin Bio, we found a perfect collaborator to jointly advance diagnostic and therapeutic medicine."

"We are excited about collaborating with Macrocyclics, a company dedicated to the leading-edge development of new chelation chemistry platforms," said Muctarr Sesay, vice president of Process Development at Goodwin Bio. "Our integrated cGMP services combined with Macrocyclics' chelation expertise will enhance clinical development programs in nuclear medicine."

Goodwin Bio, (GBI) located in Plantation, Florida, is a full service contract biomanufacturing company and specializes in process development and cGMP production of protein based therapeutics for pre-clinical and early phase clinical trials.

Macrocyclics, Dallas, Texas, a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine.